Cetuximab plus S-1 and irinotecan (IRIS) as first-line treatment in KRAS wild type metastatic colorectal cancer, a phase I/II trial (KSCC1401)

Trial Profile

Cetuximab plus S-1 and irinotecan (IRIS) as first-line treatment in KRAS wild type metastatic colorectal cancer, a phase I/II trial (KSCC1401)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Jan 2017

At a glance

  • Drugs Cetuximab (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Irinotecan (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 09 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top